earnings
confidence high
sentiment neutral
materiality 0.60
CalciMedica Q3 net loss $7.8M ($0.52/shr); cash $14.1M, funds into 2H 2026
CalciMedica, Inc.
2025-Q3 EPS
reported -$1.28
vs consensus -$0.42
▼ miss
(-204.2%)
- Net loss of $7.8M ($0.52 per share), up from $5.6M ($0.50) a year ago.
- Cash, equivalents, and short-term investments at $14.1M; expected to fund operations into 2H 2026.
- Phase 2 KOURAGE trial in AKI with respiratory failure enrollment ongoing; data expected 1H 2026.
- Positive FDA discussions on acute pancreatitis pivotal trial; final design expected 1H 2026.
- Collaboration with Telperian to leverage AI analytics for pivotal trial design.